Skyviews Life Science

One.bio is a biotechnology spinout from UC Davis that specializes in developing naturally-derived oligosaccharides for applications in food, agriculture, and biopharmaceuticals. Utilizing proprietary technology, the company creates innovative ingredients aimed at modulating the microbiome and enhancing immune function. This focus allows One.bio to provide clients with access to novel prebiotics and therapies that support both human and animal health. By unlocking the benefits of nutrition, One.bio aims to contribute to improved longevity and overall well-being.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of tissue reconstruction technologies for the reconstructive and plastic surgery markets. It focuses on tissue engineering and has created injectable 3D scaffolds designed to reconstruct soft tissue volumes lost due to tumor ablation, disease, trauma, or for aesthetic reasons. These innovative scaffolds can be injected through thin cannulas, which helps to minimize both intervention and recovery times for patients. Volumina Medical aims to address the challenges associated with the natural repair of soft tissues, offering solutions that enhance surgical outcomes.

Tropic Biosciences specializes in developing high-performing commercial varieties of tropical crops, utilizing advanced non-GMO gene editing techniques. The company focuses on promoting cultivation efficiencies to address the increasing global food demand while enhancing grower wellbeing and consumer health. By significantly accelerating the breeding process, Tropic Biosciences aims to deliver genetic improvements that empower local farming communities to produce organic crops. Their commitment to sustainable agricultural practices reflects a broader goal of improving environmental outcomes.

One.bio is a biotechnology spinout from UC Davis that specializes in developing naturally-derived oligosaccharides for applications in food, agriculture, and biopharmaceuticals. Utilizing proprietary technology, the company creates innovative ingredients aimed at modulating the microbiome and enhancing immune function. This focus allows One.bio to provide clients with access to novel prebiotics and therapies that support both human and animal health. By unlocking the benefits of nutrition, One.bio aims to contribute to improved longevity and overall well-being.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Aleph Farms Limited, based in Ashdod, Israel, is a food technology company focused on sustainable animal product innovation through cellular agriculture. Founded in 2017, Aleph Farms has pioneered the development of lab-cultured meat, notably unveiling the world’s first cultivated thin-cut steak in 2018 and the first cultivated ribeye steak in 2021. The company utilizes proprietary three-dimensional bioprinting technology to grow animal products directly from non-genetically modified cells, thereby eliminating the need for animal slaughter. Under its product brand, Aleph Cuts, Aleph Farms is set to launch the Petit Steak, which is produced from premium Angus cow cells. The company has been recognized for its commitment to climate leadership and sustainability, receiving accolades from the World Economic Forum and the United Nations for its net zero commitment made in 2020.

Aleph Farms Limited, based in Ashdod, Israel, is a food technology company focused on sustainable animal product innovation through cellular agriculture. Founded in 2017, Aleph Farms has pioneered the development of lab-cultured meat, notably unveiling the world’s first cultivated thin-cut steak in 2018 and the first cultivated ribeye steak in 2021. The company utilizes proprietary three-dimensional bioprinting technology to grow animal products directly from non-genetically modified cells, thereby eliminating the need for animal slaughter. Under its product brand, Aleph Cuts, Aleph Farms is set to launch the Petit Steak, which is produced from premium Angus cow cells. The company has been recognized for its commitment to climate leadership and sustainability, receiving accolades from the World Economic Forum and the United Nations for its net zero commitment made in 2020.

Cellares Corporation, founded in 2019 and based in South San Francisco, California, focuses on advancing cell therapy for cancer treatment by addressing the significant manufacturing challenges associated with these therapies. The company has developed the Cell Shuttle, an automated and closed end-to-end manufacturing solution designed to enhance the scalability and efficiency of cell therapy production. This innovative system allows for the simultaneous production of multiple patient doses, achieving tenfold scalability compared to traditional methods, while also reducing process failure rates by three times and lowering manufacturing costs by up to 70 percent. Cellares aims to make life-saving cell therapies more affordable and widely accessible to patients in need, thereby accelerating the development and availability of these critical treatments.

MIRAI FOODS is a cellular agriculture startup developing cultivated beef.

Ukko is a biotechnology company focused on enhancing the lives of individuals with food allergies and gluten-related disorders. Utilizing a sophisticated computational engineering platform, Ukko redesigns food allergens into therapeutics that are safe and effective. The company is developing a detailed, clinically validated map of the molecular structures associated with food allergies, which provides insights into the biological mechanisms of human-food interactions. By leveraging this information, Ukko creates modified proteins that do not provoke an immune response, offering a novel approach to treating protein-based allergies. Through the integration of artificial intelligence, immunology, computational biology, and protein engineering, Ukko aims to produce safe protein alternatives that physicians can confidently prescribe to patients.

Tropic Biosciences specializes in developing high-performing commercial varieties of tropical crops, utilizing advanced non-GMO gene editing techniques. The company focuses on promoting cultivation efficiencies to address the increasing global food demand while enhancing grower wellbeing and consumer health. By significantly accelerating the breeding process, Tropic Biosciences aims to deliver genetic improvements that empower local farming communities to produce organic crops. Their commitment to sustainable agricultural practices reflects a broader goal of improving environmental outcomes.

One.bio is a biotechnology spinout from UC Davis that specializes in developing naturally-derived oligosaccharides for applications in food, agriculture, and biopharmaceuticals. Utilizing proprietary technology, the company creates innovative ingredients aimed at modulating the microbiome and enhancing immune function. This focus allows One.bio to provide clients with access to novel prebiotics and therapies that support both human and animal health. By unlocking the benefits of nutrition, One.bio aims to contribute to improved longevity and overall well-being.

COMPASS Pathways is a mental health care company based in Cheshire, United Kingdom, with operations in the United States. The company is focused on developing innovative therapies for treatment-resistant depression (TRD) using its proprietary psilocybin formulation, COMP360. Currently undergoing Phase IIb clinical trials, COMP360 aims to provide a new treatment option for patients who have not responded to traditional depression therapies. COMPASS Pathways emphasizes the combination of psilocybin-assisted therapy with psychological support to enhance treatment efficacy. The company is committed to addressing the significant unmet needs in mental health care by advancing evidence-based solutions for those suffering from mental health challenges.